Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.56 |
| ▸ | MMP9 | P14780 | 2/20 | 0.56 |
| ▸ | MMP13 | P45452 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27166746 | 1.00 | CA2 (0.56) | CA2CA1MMP2CA12CA9 | |
| SCHEMBL1547978 | 0.87 | ALDH1A1 (0.61) | CA2CA1MMP2CA12CA9 | |
| Hydrochloric Acid SCHEMBL7362391 | 0.86 | ALDH1A1 (0.59) | CA2CA1MMP2CA12CA9 | |
| SCHEMBL30800487 | 0.84 | CA2 (0.67) | CA2CA1MMP2CA12CA9 | |
| Acetic Acid SCHEMBL8120218 | 0.84 | ALDH1A1 (0.57) | CA2CA1MMP2CA12CA9 | |
| SCHEMBL21994843 | 0.83 | CA2 (0.58) | CA2CA1MMP2CA12CA9 | |
| SCHEMBL21994845 | 0.83 | CA2 (0.58) | CA2CA1MMP2CA12CA9 | |
| SCHEMBL2775788 | 0.83 | CA2 (0.54) | CA2CA1MMP2CA12CA9 | |
| SCHEMBL31234771 | 0.82 | CA2 (0.53) | CA2CA1MMP2CA12CA9 | |
| SCHEMBL19938087 | 0.82 | CA2 (0.53) | CA2CA1MMP2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128873-A1 | HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4334295-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuoscience, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117597333-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 维吉尔神经科学股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2022236272-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | CA2 3043/4885CA1 3334/4885MMP2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.